Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

Table 6 Prediction of clinical response in DIMS0150 treated patients (n = 22) using CD163, TSP-1 and IL-6

Patient	Steroid response	Enhancing	Steroid response and enhancing
N01	1	0	0
N02	0	0	0
N03	0	0	0
N04	0	0	0
N05	0	0	0
N06	0	1	0
N07	0	0	0
N08	1	1	1
N09	0	0	0
N10	0	0	0
N11	0	0	0
N12	n.d.	n.d.	n.d.
R01	1	1	1
R02	1	0	1
R03	1	1	1
R04	1	1	1
R05	0	0	0
R06	1	1	1
R07	1	1	1
R08	1	1	1
R09	0	1	1
R10	1	1	1

(N) Clinical Non-responder defined as DIMS0150 treated patients with no clinical response at week 1 and week 4.
(R) Clinical Responder defined as DIMS0150 treated patients with a clinical response at week 1 and/or 4).
(0) Negative in classification analysis (i.e., steroid sensitive and/or not enhanced).
(1) Positive in classification analysis (i.e., steroid resistant and/or enhanced).
(n.d.) No data (no blood was received from patient for biomarker analysis).

ISSN: 1471-230X